Highlights
The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products.
Results support The Precision Peptide Company Inc.’s continued progression of its lead product toward commercial launch. Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch. Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products. Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two PhD scientists. Vancouver, British Columbia–(Newsfile Corp. – May 19, 2026) – The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “BPC”), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today reports initial third-party test results for its needle-free BPC-157 transdermal patch (the “Patch”), the Company’s lead product candidate. The Results Independent analytical laboratory Miraxis Labs, based in San Diego, California, has tested the patch and confirmed: 95.5% chromatographic purity 2.02 mg of BPC-157 per patch (quantified potency). Both results were measured using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD).
This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.
Brief Summary
The Precision Peptide Company Inc. has made significant progress with its BPC-157 transdermal patch, which has achieved an impressive 95.5% chromatographic purity. This high level of purity not only meets but exceeds the industry benchmark, positioning the Company favorably as it moves towards commercial launch.
- 95.5% chromatographic purity confirmed by Miraxis Labs
- Each patch contains 2.02 mg of BPC-157
- Independent testing enhances credibility and trust
- Needle-free design promotes consumer adoption
As the market for peptide-based solutions expands, this breakthrough could prove vital for consumer acceptance and medical use, paving the way for future innovations.
Why it matters: Achieving this purity level not only opens doors for commercial success but also enhances the reputation of The Precision Peptide Company in a competitive market.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Newsfile Corp on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.